[HTML][HTML] Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management

ZY Ma, YF Gong, HK Zhuang, ZX Zhou… - World journal of …, 2020 - ncbi.nlm.nih.gov
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with
complicated treatment options that depend on pathological grading, clinical staging, and …

Predictive factors for resistant disease with Medical/Radiologic/Liver-directed anti-tumor treatments in patients with advanced pancreatic neuroendocrine neoplasms …

L Lee, I Ramos-Alvarez, RT Jensen - Cancers, 2022 - mdpi.com
Simple Summary Tumor resistance, both primary and acquired, is leading to increased
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …

Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases …

Y Liu, H Liu, W Chen, H Yu, W Yao, W Fan… - Cancer …, 2022 - Wiley Online Library
Objective To evaluate the efficacy and outcome of transarterial embolization (TAE) plus
octreotide long‐acting repeatable (LAR) on patients with low‐to‐intermediate …

Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors

M Ronot, MD Burgio, J Gregory, O Hentic… - Best Practice & …, 2023 - Elsevier
Neuroendocrine tumors (NETs) are relatively rare neoplasms displaying heterogeneous
clinical behavior, ranging from indolent to aggressive forms. Patients diagnosed with NETs …

A nomogram to predict individual survival of patients with liver-limited metastases from gastroenteropancreatic neuroendocrine neoplasms: a US population-based …

G Xu, Y Xiao, H Hu, B Jin, X Wu, X Wan, Y Zheng… - …, 2022 - karger.com
Introduction: Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) with
liver metastasis encompass a wide variety of clinical conditions with various prognosis, no …

Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases

FT Lee, J Williams, R Nordgren, JL Schwarz… - The American Journal of …, 2024 - Elsevier
Background Reported outcomes after surgical debulking in patients with advanced
neuroendocrine tumor liver metastases (NETLM) are sparse. Methods NETLM patients that …

Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings

A Baghdadi, M Ghadimi, S Mirpour, B Hazhirkarzar… - Surgical Oncology, 2021 - Elsevier
Neuroendocrine tumors (NET) are a group of neoplasms with neuroendocrine differentiation
affecting a wide range of organs. Functional NETs present with symptoms due to the …

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience

V Sukrithan, H Armbruster, S Rogers, SM Vogt… - Plos one, 2024 - journals.plos.org
Peptide receptor radionucleotide therapy (PRRT) with 177Lu-dotatate is widely used for the
treatment of patients with neuroendocrine tumors (NETs). We analyzed data from 104 …

Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment

J Assouline, R Cannella, G Porrello… - Radiology: Imaging …, 2023 - pubs.rsna.org
Purpose To investigate whether liver enhancing tumor burden (LETB) assessed at contrast-
enhanced CT indicates early response and helps predict survival outcomes in patients with …

Analysis of tumor burden as a biomarker for patient survival with neuroendocrine tumor liver metastases undergoing intra-arterial therapies: a single-center …

M Miszczuk, J Chapiro, D Do Minh… - Cardiovascular and …, 2022 - Springer
Purpose To assess the value of quantitative analysis of tumor burden on baseline MRI for
prediction of survival in patients with neuroendocrine tumor liver metastases (NELM) …